Encodar is the trade name and its generic name is Bevacizumab, which is used to treat metastatic colorectal cancer and some non-small cell lung cancers. Bevacizumab is used clinically in combination with fluoropyrimidine-based chemotherapy for the treatment of metastatic colorectal cancer and in combination with platinum-based chemotherapy for the treatment of advanced, metastatic, or recurrent non-squamous cell non-small cell carcinomas, but is contraindicated in those who are allergic to any of the components of the drug. Patients taking the drug may be at increased risk of gastrointestinal perforation and gallbladder perforation, and the drug will need to be permanently discontinued if these occur. Patients taking the drug for treatment may also be at increased risk of developing fistulae and will also need to permanently discontinue the drug if they develop a tracheoesophageal fistula or any of the grade 4 fistulae. Discontinuation should be considered for patients who develop internal fistulas outside the gastrointestinal tract. In addition, treatment with this drug increases the risk of bleeding, and if patients experience grade 3 or 4 bleeding during treatment, the drug also needs to be permanently discontinued. Patients are advised to use Bevacizumab strictly under the supervision of a doctor and to pay attention to its related matters and avoid unauthorized changes in the dose of the drug.